LeMaitre Vascular (NASDAQ:LMAT) Sees Strong Trading Volume - What's Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 253,150 shares changed hands during mid-day trading, an increase of 99% from the previous session's volume of 127,513 shares.The stock last traded at $90.91 and had previously closed at $92.10.

Analysts Set New Price Targets

Several research analysts recently issued reports on LMAT shares. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective on the stock. Oppenheimer restated an "outperform" rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research lifted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Finally, JMP Securities raised their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Price Performance

The firm's 50-day moving average price is $97.70 and its 200-day moving average price is $89.71. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 49.86, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular's revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were paid a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular's dividend payout ratio is presently 34.97%.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.79% of the company's stock.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of LMAT. Franklin Resources Inc. increased its holdings in LeMaitre Vascular by 5.2% in the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier's stock valued at $1,165,000 after buying an additional 627 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $181,000. Geode Capital Management LLC raised its position in shares of LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock valued at $50,403,000 after acquiring an additional 23,443 shares in the last quarter. M&T Bank Corp bought a new position in LeMaitre Vascular during the third quarter worth $1,551,000. Finally, Barclays PLC raised its holdings in shares of LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after purchasing an additional 29,180 shares during the period. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.